

Harliku[™] (nitisinone) - New indication, new formulation

- On June 10, 2025, the <u>FDA approved</u> Cycle Pharmaceuticals' <u>Harliku (nitisinone)</u> tablets, for the reduction of urine homogentisic acid (HGA) in adult patients with alkaptonuria (AKU).
- Nitisinone tablets are also approved under the brand name Nityr® for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.
- The approval of Harliku was based on an open-label, randomized, no-treatment controlled trial in 40 adult patients diagnosed with AKU. Patients received either Harliku or no treatment for three years.
 - Harliku was effective at reducing levels of urinary HGA. The Harliku group had an average percent reduction from baseline of 88% (95% CI: 79, 97) after 1 year of treatment, which was sustained through three years of treatment with an average percent reduction from baseline of 91% at year 3 (95% CI: 85, 97). In contrast, the untreated controls had an average increase of 107% from baseline to year 1 (95% CI: 0, 216) and 108% from baseline to year 3 (95% CI: 19, 198).
- The most common adverse reactions (> 1%) with Harliku use were elevated tyrosine levels, keratitis and thrombocytopenia.
- The recommended dosage of Harliku is 2 mg administered orally, once daily.
- Cycle Pharmaceuticals' launch plans for Harliku are pending. Harliku will be available as a 2 mg tablet.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.